Scheduling, administration, biomarkers, and practical guidance.
Most conservative starting dose with refined Phase 3 TRIUMPH steps (including 9 mg) to smooth metabolic adaptation and minimize dysesthesia risk.
Follows the clinical decision algorithm used in specific high-efficacy sub-studies. Omits 6 mg and 9 mg steps. For patients with prior GLP-1 agonist experience and good GI tolerance.
Once weekly on the same day each week
Morning administration allows monitoring of any acute GI or neurological effects during waking hours. Consistent day-of-week dosing maintains steady-state pharmacokinetics.